To assess whether patients can mediate an appropriate immune response KLH Week 4 post vaccination [clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae]

To assess whether patients can mediate an appropriate immune response KLH Week 4 post vaccination [clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae]

Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae
Vaccination With Tetanus and KLH to Assess Immune Responses. [clinicaltrials:NCT00000105]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To assess whether patients can mediate an appropriate immune response KLH Week 4 post vaccination [clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae]

Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae
Bio2RDF identifier
1fb22305469ddfca23c01c162a1d8dae
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae
measure [clinicaltrials_vocabulary:measure]
To assess whether patients can mediate an appropriate immune response KLH
time frame [clinicaltrials_vocabulary:time-frame]
description
Intracel KLH 1000 mcg (1 mg) w ...... arly (this arm closed 1/2/02).
identifier
clinicaltrials_resource:1fb22305469ddfca23c01c162a1d8dae
title
To assess whether patients can ...... se KLH Week 4 post vaccination
@en
inDataset
type
label
To assess whether patients can ...... 22305469ddfca23c01c162a1d8dae]
@en